High Yield of Functional Dopamine-like Neurons Obtained in NeuroForsk 2.0 Medium to Study Acute and Chronic Rotenone Effects on Oxidative Stress, Autophagy, and Apoptosis
<p>Immunofluorescence analysis, percentage expression of neuronal lineage and dopaminergic markers in MenSCs differentiated into dopamine-like neurons (DALNs). MenSCs were cultured in RCm, NB-B27, NeuroForsk or NeuroForsk 2.0 medium as described in the <a href="#sec4-ijms-24-15744" class="html-sec">Section 4</a>. After this time, cells were single- or double-stained as indicated in the figure with primary antibodies against neurofilament light chain (NFL), tyrosine hydroxylase (TH), and dopamine transporter (DAT). (<b>A</b>) Representative density plot figures showing the NFL of single-stained NFL in RCm, NB-B27, NeuroForsk, or NeuroForsk 2.0 medium cultured MenSCs at day 7. (<b>B</b>) Percentage of NFL-positive cells in RCm, NB-B27, NeuroForsk, and NeuroForsk 2.0 medium-cultured MenSCs at day 7. (<b>C</b>) Representative fluorescence microscopy photographs showing MenSCs cultured in RCm (black bar), NB-B27 (<span style="color:#00B050">green</span> bar), NeuroForsk (<span style="color:#0070C0">blue</span> bar), and NeuroForsk 2.0 (<span style="color:red">red</span> bar) incubated with primary antibodies against NFL (<span style="color:red">red</span>) at day 7. The nuclei were stained with Hoechst. (<b>D</b>) Mean fluorescence intensity (MFI) quantification of images obtained by immunofluorescence analysis. (<b>E</b>) Representative density plot figures showing the TH/DAT double-positive population in RCm, NB-B27, NeuroForsk, or NeuroForsk 2.0 medium-cultured MenSCs at day 7. (<b>F</b>) Percentage of TH/DAT double-positive cells in RCm (black bar), NB-B27 (<span style="color:#00B050">green</span> bar), NeuroForsk (<span style="color:#0070C0">blue</span> bar), and NeuroForsk 2.0 (<span style="color:red">red</span> bar) medium-cultured MenSCs at day 7. (<b>G</b>) Representative fluorescence microscopy photographs showing MenSCs cultured in RCm, NB-B27, NeuroForsk, and NeuroForsk 2.0 medium incubated with primary antibodies against TH (<span style="color:#00B050">green</span>) and DAT (<span style="color:red">red</span>) at day 7. The nuclei were stained with Hoechst. (<b>H</b>,<b>I</b>) Mean fluorescence intensity (MFI) quantification of images obtained by immunofluorescence analysis. The figures represent 1 out of 3 independent experiments. One-way ANOVA, post hoc test Bonferroni. Data are presented as mean ± SD (* <span class="html-italic">p</span> < 0.05; ** <span class="html-italic">p</span> < 0.01; *** <span class="html-italic">p</span> < 0.001). Image magnification, 200×. +++ symbols and numbers in the figure represent positive cellular population for the tested marker.</p> "> Figure 1 Cont.
<p>Immunofluorescence analysis, percentage expression of neuronal lineage and dopaminergic markers in MenSCs differentiated into dopamine-like neurons (DALNs). MenSCs were cultured in RCm, NB-B27, NeuroForsk or NeuroForsk 2.0 medium as described in the <a href="#sec4-ijms-24-15744" class="html-sec">Section 4</a>. After this time, cells were single- or double-stained as indicated in the figure with primary antibodies against neurofilament light chain (NFL), tyrosine hydroxylase (TH), and dopamine transporter (DAT). (<b>A</b>) Representative density plot figures showing the NFL of single-stained NFL in RCm, NB-B27, NeuroForsk, or NeuroForsk 2.0 medium cultured MenSCs at day 7. (<b>B</b>) Percentage of NFL-positive cells in RCm, NB-B27, NeuroForsk, and NeuroForsk 2.0 medium-cultured MenSCs at day 7. (<b>C</b>) Representative fluorescence microscopy photographs showing MenSCs cultured in RCm (black bar), NB-B27 (<span style="color:#00B050">green</span> bar), NeuroForsk (<span style="color:#0070C0">blue</span> bar), and NeuroForsk 2.0 (<span style="color:red">red</span> bar) incubated with primary antibodies against NFL (<span style="color:red">red</span>) at day 7. The nuclei were stained with Hoechst. (<b>D</b>) Mean fluorescence intensity (MFI) quantification of images obtained by immunofluorescence analysis. (<b>E</b>) Representative density plot figures showing the TH/DAT double-positive population in RCm, NB-B27, NeuroForsk, or NeuroForsk 2.0 medium-cultured MenSCs at day 7. (<b>F</b>) Percentage of TH/DAT double-positive cells in RCm (black bar), NB-B27 (<span style="color:#00B050">green</span> bar), NeuroForsk (<span style="color:#0070C0">blue</span> bar), and NeuroForsk 2.0 (<span style="color:red">red</span> bar) medium-cultured MenSCs at day 7. (<b>G</b>) Representative fluorescence microscopy photographs showing MenSCs cultured in RCm, NB-B27, NeuroForsk, and NeuroForsk 2.0 medium incubated with primary antibodies against TH (<span style="color:#00B050">green</span>) and DAT (<span style="color:red">red</span>) at day 7. The nuclei were stained with Hoechst. (<b>H</b>,<b>I</b>) Mean fluorescence intensity (MFI) quantification of images obtained by immunofluorescence analysis. The figures represent 1 out of 3 independent experiments. One-way ANOVA, post hoc test Bonferroni. Data are presented as mean ± SD (* <span class="html-italic">p</span> < 0.05; ** <span class="html-italic">p</span> < 0.01; *** <span class="html-italic">p</span> < 0.001). Image magnification, 200×. +++ symbols and numbers in the figure represent positive cellular population for the tested marker.</p> "> Figure 2
<p>Evaluation of dopamine (DA) response in dopamine-like neurons (DALNs). (<b>A</b>) MenSCs were cultured in RCm, NB-B27, NeuroForsk and NeuroForsk 2.0 medium as described in <a href="#sec4-ijms-24-15744" class="html-sec">Section 4</a>. Time-lapse images (0, 10, 40, 60, 80, 100 and 120 s) of Ca<sup>2+</sup> fluorescence in MenSC cultured in RCm, NB-B27, NeuroForsk, and NeuroForsk 2.0 medium at day 7 (<span class="html-italic">n</span> = 30 cells imaged, N = 3 dishes) as a response to dopamine (DA) treatment. DA was puffed into the culture at 0 s. Then, the Ca<sup>2+</sup> fluorescence of cells was monitored at the indicated times. Color contrast indicates fluorescence intensity: <span style="color:#002060">dark blue</span> < <span style="color:#00B0F0">light blue</span> < <span style="color:#00B050">green</span> < <span style="color:#FFC000">yellow</span> < <span style="color:red">red</span>. (<b>B</b>) Normalized mean fluorescence signal (ΔF/F) over time, indicating temporal cytoplasmic Ca<sup>2+</sup> elevation in response to DA treatment. The figures represent 1 out of 3 independent experiments. Data are presented as mean (<span class="html-italic">n</span> = 3). Image magnification, 200×.</p> "> Figure 3
<p>Acute and chronic exposure to rotenone induces significant ΔΨm damage and increased PRKN expression in DANLs. (<b>A</b>) Representative flow cytometry contour plots showing the percentage of MitoTracker of untreated DALNs or those treated with ROT (50 µM) for 6 h and untreated or those treated with ROT (10 µM) for 24 h. (<b>B</b>) Percentage of MitoTracker-positive cells. (<b>C</b>) Representative flow cytometry contour plots showing untreated DALNs or those treated with ROT (50 µM) for 6 h and untreated or those treated with ROT (10 µM) for 24 h and stained with primary antibody against parkin (PRKN). (<b>D</b>) Percentage of PRKN-positive cells. (<b>E</b>) Representative fluorescence microscopy photographs showing untreated DALNs or those treated with ROT (50 µM) for 6 h and untreated or those treated with ROT (10 µM) for 24 h, and stained with MitoTracker. Positive <span style="color:red">red</span> fluorescence reflects high mitochondrial membrane potential ΔΨ<sub>m</sub>, and positive <span style="color:#0033CC">blue</span> fluorescence reflects nuclei. (<b>F</b>) Quantification of the MitoTracker mean fluorescence intensity (MFI) in untreated and treated DANLs. (<b>G</b>) Representative fluorescence microscopy photographs showing untreated DALNs or those treated with ROT (50 µM) for 6 h and untreated or those treated with ROT (10 µM) for 24 h and stained with primary antibody against parkin (PRKN). Positive <span style="color:#0033CC">blue</span> fluorescence reflects nuclei, positive <span style="color:#00B050">green</span> fluorescence reflects the presence of PRKN protein. (<b>H</b>) Quantification of the PRKN mean fluorescence intensity (MFI) in untreated and treated DANLs. The figures represent 1 out of 3 independent experiments. One-way ANOVA, followed by Tukey’s test. Statistically significant differences: ** <span class="html-italic">p</span> < 0.01, and <span class="html-italic">p</span> *** < 0.001. Image magnification, 200×. The contour diagrams, histograms, bars, dot graphs, and photomicrographs represent one out of three independent experiments (<span class="html-italic">n</span> = 3). The data are presented as mean ± SD of three independent experiments. SD represents <5%. ++, +++ symbols and numbers in the figure represent positive cellular population for the tested marker.</p> "> Figure 3 Cont.
<p>Acute and chronic exposure to rotenone induces significant ΔΨm damage and increased PRKN expression in DANLs. (<b>A</b>) Representative flow cytometry contour plots showing the percentage of MitoTracker of untreated DALNs or those treated with ROT (50 µM) for 6 h and untreated or those treated with ROT (10 µM) for 24 h. (<b>B</b>) Percentage of MitoTracker-positive cells. (<b>C</b>) Representative flow cytometry contour plots showing untreated DALNs or those treated with ROT (50 µM) for 6 h and untreated or those treated with ROT (10 µM) for 24 h and stained with primary antibody against parkin (PRKN). (<b>D</b>) Percentage of PRKN-positive cells. (<b>E</b>) Representative fluorescence microscopy photographs showing untreated DALNs or those treated with ROT (50 µM) for 6 h and untreated or those treated with ROT (10 µM) for 24 h, and stained with MitoTracker. Positive <span style="color:red">red</span> fluorescence reflects high mitochondrial membrane potential ΔΨ<sub>m</sub>, and positive <span style="color:#0033CC">blue</span> fluorescence reflects nuclei. (<b>F</b>) Quantification of the MitoTracker mean fluorescence intensity (MFI) in untreated and treated DANLs. (<b>G</b>) Representative fluorescence microscopy photographs showing untreated DALNs or those treated with ROT (50 µM) for 6 h and untreated or those treated with ROT (10 µM) for 24 h and stained with primary antibody against parkin (PRKN). Positive <span style="color:#0033CC">blue</span> fluorescence reflects nuclei, positive <span style="color:#00B050">green</span> fluorescence reflects the presence of PRKN protein. (<b>H</b>) Quantification of the PRKN mean fluorescence intensity (MFI) in untreated and treated DANLs. The figures represent 1 out of 3 independent experiments. One-way ANOVA, followed by Tukey’s test. Statistically significant differences: ** <span class="html-italic">p</span> < 0.01, and <span class="html-italic">p</span> *** < 0.001. Image magnification, 200×. The contour diagrams, histograms, bars, dot graphs, and photomicrographs represent one out of three independent experiments (<span class="html-italic">n</span> = 3). The data are presented as mean ± SD of three independent experiments. SD represents <5%. ++, +++ symbols and numbers in the figure represent positive cellular population for the tested marker.</p> "> Figure 4
<p>TOMM20 and DRP1 colocalize in DANLs cells exposed to acute and chronic ROT doses. (<b>A</b>) Representative fluorescence microscopy photographs showing untreated DALNs or those treated with (50 µM) ROT for 6, stained with primary antibodies against DRP1 (<span style="color:#00B050">green</span> fluorescence image) and TOMM20 (<span style="color:red">red</span> fluorescence image). Image of colocalization of DRP1 and mitochondrial TOMM20 and merged image. Image of colocalization of nuclei (Hoechst) and DRP1. Image of colocalization of mitochondria and DRP1. (<b>B</b>) Percentage of localization area of colocalization of DRP1/mitochondria. (<b>C</b>) Representative fluorescence microscopy photographs showing untreated DALNs or those treated with 10 µM ROT for 24 h, stained with primary antibodies against DRP1 (<span style="color:#00B050">green</span> fluorescence image) and TOMM20 (<span style="color:red">red</span> fluorescence image). Image of colocalization of DRP1 and mitochondrial TOMM20 and merged image. Image of colocalization of nuclei (Hoechst) and DRP1. Image of colocalization of mitochondria and DRP1. (<b>D</b>) Percentage of localization area of colocalization of DRP1/mitochondria. The image represents one out of three independent experiments (<span class="html-italic">n</span> = 3). One-way ANOVA test showed a statistically significant intragroup and intergroup (Tukey’s multiple comparison test, <span class="html-italic">p</span> = 0.003) differences. Statistically significant differences: * <span class="html-italic">p</span> < 0.05, and <span class="html-italic">p</span> *** < 0.001. The data are presented as mean ± SD of three independent experiments. Image magnification, 400×.</p> "> Figure 5
<p>DALNs show a high oxidation of DJ-1 under acute but moderate under chronic ROT exposure. (<b>A</b>) Representative flow cytometry contour plots showing untreated DALNs or those treated with ROT (50 µM) for 6 h and untreated DALNs or those treated with ROT (10 µM) for 24 h, and stained with primary antibody against oxidized protein DJ-1 (DJ-1Cys<sup>106</sup>-SO<sub>3</sub>, oxDJ-1). (<b>B</b>) Percentage of DJ-1Cys<sup>106</sup>-SO<sub>3</sub>-positive cells. (<b>C</b>) Representative fluorescence microscopy photographs showing untreated DANLs or those treated with ROT (50 µM) for 6 h and untreated DANLs or those treated with ROT (10 µM) for 24 h and stained with Hoechst (<span style="color:#0033CC">blue</span>) and primary antibodies against oxDJ-1 (<span style="color:#00B050">green</span>). Positive <span style="color:#0033CC">blue</span> fluorescence reflects nuclei and positive <span style="color:#00B050">green</span> fluorescence reflects the presence of oxDJ-1. (<b>D</b>) Quantification of the oxDJ-1. The data are presented as the mean ± SD of three independent experiments (<span class="html-italic">n</span> = 3). One-way ANOVA followed by Tukey’s test: Statistically significant differences: * <span class="html-italic">p</span> < 0.05; ** <span class="html-italic">p</span> < 0.01, *** <span class="html-italic">p</span> < 0.001. Image magnification, 200×. +, ++ symbols and numbers in the figure represent positive cellular population for the tested marker.</p> "> Figure 6
<p>DALNs show a high oxidation of phosphorylation of LRRK2 and phosphorylation of α-Syn under acute but moderate under chronic ROT exposure. (<b>A</b>) Representative flow cytometry contour plots showing untreated DALNs or those treated with ROT (50 µM) for 6 h and untreated DALNs or those treated with ROT (10 µM) for 24 h, and stained with primary antibody against phosphorylated LRRK2 (pS<sup>935</sup>-LRRK2). (<b>B</b>) Percentage of pS<sup>935</sup>-LRRK2-positive cells. (<b>C</b>) Representative flow cytometry contour plots showing untreated DALNs or those treated with ROT (50 µM) for 6 h, and untreated DALNs or those treated with ROT (10 µM) for 24 h and stained with primary antibody against naïve LRRK2. (<b>D</b>) Percentage of LRRK2-positive cells. (<b>E</b>) Representative fluorescence microscopy photographs showing untreated DANLs or those treated with ROT (50 µM) for 6 h and untreated DANLs or those treated with ROT (10 µM) for 24 h and stained with Hoechst and primary antibodies against pS<sup>935</sup>-LRRK2 and naïve LRRK2. Positive <span style="color:#0033CC">blue</span> fluorescence reflects nuclei, positive <span style="color:#00B050">green</span> fluorescence reflects the presence of pS<sup>935</sup>-LRRK2, and positive <span style="color:red">red</span> fluorescence reflects t-LRRK2 protein. (<b>F</b>,<b>G</b>) Mean fluorescence intensity (MFI) in untreated or treated DANLs. (<b>H</b>) Representative flow cytometry contour plots showing untreated DALNs or those treated with ROT (50 µM) for 6 h and untreated DALNs or those treated with ROT (10 µM) for 24 h and stained with primary antibody against phosphorylated α-synuclein (pS<sup>129</sup>-αSYN). (<b>I</b>) Percentage of pS<sup>129</sup>-αSYN-positive cells. (<b>J</b>) Representative flow cytometry contour plots showing untreated DALNs or those treated with ROT (50 µM) for 6 h and untreated DALNs or those treated with ROT (10 µM) for 24 h and stained with primary antibody against naïve αSYN. (<b>K</b>) Percentage of total- αSYN-positive cells. (<b>L</b>) Representative fluorescence microscopy photographs showing untreated DANLs or those treated with ROT (50 µM) for 6 h and untreated DANLs or those treated with ROT (10 µM) for 24 h and stained with Hoechst and primary antibodies against pS<sup>129</sup>-αSYN and naïve αSYN. Positive <span style="color:#0033CC">blue</span> fluorescence reflects nuclei, positive <span style="color:#00B050">green</span> fluorescence reflects the presence of pS<sup>129</sup>-αSYN, and positive <span style="color:red">red</span> fluorescence reflects total αSYN protein. (<b>M</b>,<b>N</b>) Mean fluorescence intensity (MFI) in untreated or treated DANLs. The data are presented as the mean ± SD of three independent experiments (<span class="html-italic">n</span> = 3). One-way ANOVA followed by Tukey’s test. Statistically significant differences: * <span class="html-italic">p</span> < 0.05; *** <span class="html-italic">p</span> < 0.001. Image magnification, 200×. + symbol and numbers in the figure represent positive cellular population for the tested marker.</p> "> Figure 6 Cont.
<p>DALNs show a high oxidation of phosphorylation of LRRK2 and phosphorylation of α-Syn under acute but moderate under chronic ROT exposure. (<b>A</b>) Representative flow cytometry contour plots showing untreated DALNs or those treated with ROT (50 µM) for 6 h and untreated DALNs or those treated with ROT (10 µM) for 24 h, and stained with primary antibody against phosphorylated LRRK2 (pS<sup>935</sup>-LRRK2). (<b>B</b>) Percentage of pS<sup>935</sup>-LRRK2-positive cells. (<b>C</b>) Representative flow cytometry contour plots showing untreated DALNs or those treated with ROT (50 µM) for 6 h, and untreated DALNs or those treated with ROT (10 µM) for 24 h and stained with primary antibody against naïve LRRK2. (<b>D</b>) Percentage of LRRK2-positive cells. (<b>E</b>) Representative fluorescence microscopy photographs showing untreated DANLs or those treated with ROT (50 µM) for 6 h and untreated DANLs or those treated with ROT (10 µM) for 24 h and stained with Hoechst and primary antibodies against pS<sup>935</sup>-LRRK2 and naïve LRRK2. Positive <span style="color:#0033CC">blue</span> fluorescence reflects nuclei, positive <span style="color:#00B050">green</span> fluorescence reflects the presence of pS<sup>935</sup>-LRRK2, and positive <span style="color:red">red</span> fluorescence reflects t-LRRK2 protein. (<b>F</b>,<b>G</b>) Mean fluorescence intensity (MFI) in untreated or treated DANLs. (<b>H</b>) Representative flow cytometry contour plots showing untreated DALNs or those treated with ROT (50 µM) for 6 h and untreated DALNs or those treated with ROT (10 µM) for 24 h and stained with primary antibody against phosphorylated α-synuclein (pS<sup>129</sup>-αSYN). (<b>I</b>) Percentage of pS<sup>129</sup>-αSYN-positive cells. (<b>J</b>) Representative flow cytometry contour plots showing untreated DALNs or those treated with ROT (50 µM) for 6 h and untreated DALNs or those treated with ROT (10 µM) for 24 h and stained with primary antibody against naïve αSYN. (<b>K</b>) Percentage of total- αSYN-positive cells. (<b>L</b>) Representative fluorescence microscopy photographs showing untreated DANLs or those treated with ROT (50 µM) for 6 h and untreated DANLs or those treated with ROT (10 µM) for 24 h and stained with Hoechst and primary antibodies against pS<sup>129</sup>-αSYN and naïve αSYN. Positive <span style="color:#0033CC">blue</span> fluorescence reflects nuclei, positive <span style="color:#00B050">green</span> fluorescence reflects the presence of pS<sup>129</sup>-αSYN, and positive <span style="color:red">red</span> fluorescence reflects total αSYN protein. (<b>M</b>,<b>N</b>) Mean fluorescence intensity (MFI) in untreated or treated DANLs. The data are presented as the mean ± SD of three independent experiments (<span class="html-italic">n</span> = 3). One-way ANOVA followed by Tukey’s test. Statistically significant differences: * <span class="html-italic">p</span> < 0.05; *** <span class="html-italic">p</span> < 0.001. Image magnification, 200×. + symbol and numbers in the figure represent positive cellular population for the tested marker.</p> "> Figure 7
<p>DALNs show high-oxidation cleaved caspase 3 (CC3) under acute and chronic ROT exposure. (<b>A</b>) Representative flow cytometry contour plots showing untreated DALNs or those treated with ROT (50 µM) for 6 h and untreated DALNs or those treated with ROT (10 µM) for 24 h and stained with primary antibody against cleaved caspase-3 (CC3). (<b>B</b>) Percentage of CC3-positive cells. (<b>C</b>) Representative fluorescence microscopy photographs showing untreated DANLs or those treated with ROT (50 µM) for 6 h and untreated DANLs or those treated with ROT (10 µM) for 24 h and stained with Hoechst and primary antibodies against protein CC3 (<span style="color:#00B050">green</span>). Positive blue fluorescence reflects nuclei, positive <span style="color:#00B050">green</span> fluorescence reflects the presence of CC3 protein. (<b>D</b>) Mean fluorescence intensity (MFI) in untreated or treated DANLs. The data are presented as the mean ± SD of three independent experiments (<span class="html-italic">n</span> = 3). One-way ANOVA followed by Tukey’s test: Statistically significant differences: *** <span class="html-italic">p</span> < 0.001. Image magnification, 200×. +, ++ symbols and numbers in the figure represent positive cellular population for the tested marker.</p> "> Figure 8
<p>Chronic ROT exposure increases lipidated LC3B more than acute conditions in DALNs. (<b>A</b>) Representative contour 2D plots showing the percentage of lapidated LC3B of untreated DALNs or those treated with ROT (50 μM) for 6 h, (<b>B</b>) untreated DALNs or those treated with ROT (10 μM) for 24 h, (<b>C</b>) rapamycin (RAP, 10 nM), (<b>D</b>) bafilomycin A1 (BAF, 10 nM) for 24 h. (<b>E</b>) Percentage of LC3B-positive cells. The data are presented as the mean ± SD of three independent experiments (<span class="html-italic">n</span> = 3). One-way ANOVA followed by Tukey’s test. Statistically significant differences: *** <span class="html-italic">p</span> < 0.001. +, ++ symbols and numbers in the figure represent positive cellular population for the tested marker.</p> "> Figure 9
<p>Chronic rotenone exposure induces a higher accumulation of lysosomes than acute conditions in DALN. (<b>A</b>) Representative immunofluorescence images showing lysosomal accumulation by Lysotracker<sup>®</sup> stain in untreated DANLs or those treated with ROT (50 μM) for 6 h; (<b>B</b>) untreated DANLs or those treated with ROT (10 μM), (<b>C</b>) rapamycin (RAP, 10 nM), and (<b>D</b>) bafilomycin A1 (BAF, 10 nM) for 24 h. Positive <span style="color:#0033CC">blue</span> fluorescence reflects nuclei, positive <span style="color:#00B050">green</span> fluorescence reflects the Lysotracker stain. (<b>E</b>) Quantitative analysis of Lysotracker<sup>®</sup> accumulation as mean fluorescence intensity. The data are presented as the mean ± SD of three independent experiments (<span class="html-italic">n</span> = 3). One-way ANOVA followed by Tukey’s test. Statistically significant differences: * <span class="html-italic">p</span> < 0.05, *** <span class="html-italic">p</span> < 0.001. Image magnification, 200×.</p> "> Figure 10
<p>The inhibitor LRRK2 PF-06447475 (PF-475) inhibits pS<sup>935</sup>-LRKK2, and cleaved caspase 3 in DALNs treated with ROT. (<b>A</b>) Representative flow cytometry contour plots showing untreated DALNs or those treated with ROT (50 µM) in the absence or presence of PF-475 for 6 h, and stained with primary antibody against p-S<sup>935</sup>-LRKK2. (<b>B</b>) Percentage of p-S<sup>935</sup>-LRKK2-positive cells in untreated cells and cells treated with ROT and/or PF-475. (<b>C</b>) Representative flow cytometry contour plots showing untreated DALNs or those treated with ROT (10 µM) in the absence or presence of PF-475 for 6 h and stained with primary antibody against total-LRKK2. (<b>D</b>) Percentage of total LRKK2-positive cells in untreated cells and cells treated with ROT and/or PF475. (<b>E</b>) Representative flow cytometry contour plots showing untreated DALNs or those treated with ROT (10 µM) in the absence or presence of PF-475 for 24 h, and stained with primary antibody against p-S<sup>935</sup>-LRKK2; (<b>F</b>) Percentage of p-S<sup>935</sup> LRKK2-positive cells in untreated cells and cells treated with ROT and/or PF-475. (<b>G</b>) Representative flow cytometry contour plots showing untreated DALNs or those treated with ROT (10 µM) in the absence or presence of PF-475 for 24 h and stained with primary antibody against total-LRKK2. (<b>H</b>) Percentage of total LRKK2-positive cells in untreated cells and cells treated with ROT and/or PF-475. (<b>I</b>) Representative flow cytometry contour plots showing untreated DALNs or those treated with ROT (50 µM) in the absence or presence of PF-475 for 6 h and stained with primary antibody against CC3; (<b>J</b>) Percentage of CC3-positive cells in untreated cells and cells treated with ROT and/or PF-475. (<b>K</b>) Representative flow cytometry contour plots showing untreated DALNs or those treated with ROT (10 µM) in the absence or presence of PF-475 for 24 h, and stained with primary antibody against CC3. (<b>L</b>) Percentage of CC3-positive cells in untreated cells and cells treated with ROT and/or PF-475. The data are presented as the mean ± SD of three independent experiments (<span class="html-italic">n</span> = 3). One-way ANOVA followed by Tukey’s test. Statistically significant differences: ** <span class="html-italic">p</span> < 0.01; *** <span class="html-italic">p</span> < 0.001. ++ symbol and numbers in the figure represent positive cellular population for the tested marker.</p> "> Figure 10 Cont.
<p>The inhibitor LRRK2 PF-06447475 (PF-475) inhibits pS<sup>935</sup>-LRKK2, and cleaved caspase 3 in DALNs treated with ROT. (<b>A</b>) Representative flow cytometry contour plots showing untreated DALNs or those treated with ROT (50 µM) in the absence or presence of PF-475 for 6 h, and stained with primary antibody against p-S<sup>935</sup>-LRKK2. (<b>B</b>) Percentage of p-S<sup>935</sup>-LRKK2-positive cells in untreated cells and cells treated with ROT and/or PF-475. (<b>C</b>) Representative flow cytometry contour plots showing untreated DALNs or those treated with ROT (10 µM) in the absence or presence of PF-475 for 6 h and stained with primary antibody against total-LRKK2. (<b>D</b>) Percentage of total LRKK2-positive cells in untreated cells and cells treated with ROT and/or PF475. (<b>E</b>) Representative flow cytometry contour plots showing untreated DALNs or those treated with ROT (10 µM) in the absence or presence of PF-475 for 24 h, and stained with primary antibody against p-S<sup>935</sup>-LRKK2; (<b>F</b>) Percentage of p-S<sup>935</sup> LRKK2-positive cells in untreated cells and cells treated with ROT and/or PF-475. (<b>G</b>) Representative flow cytometry contour plots showing untreated DALNs or those treated with ROT (10 µM) in the absence or presence of PF-475 for 24 h and stained with primary antibody against total-LRKK2. (<b>H</b>) Percentage of total LRKK2-positive cells in untreated cells and cells treated with ROT and/or PF-475. (<b>I</b>) Representative flow cytometry contour plots showing untreated DALNs or those treated with ROT (50 µM) in the absence or presence of PF-475 for 6 h and stained with primary antibody against CC3; (<b>J</b>) Percentage of CC3-positive cells in untreated cells and cells treated with ROT and/or PF-475. (<b>K</b>) Representative flow cytometry contour plots showing untreated DALNs or those treated with ROT (10 µM) in the absence or presence of PF-475 for 24 h, and stained with primary antibody against CC3. (<b>L</b>) Percentage of CC3-positive cells in untreated cells and cells treated with ROT and/or PF-475. The data are presented as the mean ± SD of three independent experiments (<span class="html-italic">n</span> = 3). One-way ANOVA followed by Tukey’s test. Statistically significant differences: ** <span class="html-italic">p</span> < 0.01; *** <span class="html-italic">p</span> < 0.001. ++ symbol and numbers in the figure represent positive cellular population for the tested marker.</p> "> Figure 11
<p>The inhibitor LRRK2 PF-06447475 (PF-475) affects the accumulation of lysosomes in DALNs treated with ROT. (<b>A</b>) Representative flow cytometry contour plots showing untreated DALNs or those treated with ROT (50 µM) in the absence or presence of PF-475 for 6 h and stained with Lysotracker<sup>®</sup>. (<b>B</b>) Percentage of Lysotracker<sup>®</sup> stain-positive cells in untreated cells and cells treated with ROT and/or PF-475. (<b>C</b>) Representative flow cytometry contour plots showing untreated DALNs or those treated with ROT (10 µM) in the absence or presence of PF-475 for 24 h, and stained with Lysotracker<sup>®</sup>. (<b>D</b>) Percentage of Lysotracker<sup>®</sup> stain-positive cells in untreated cells and cells treated with ROT and/or PF-475. The data are presented as the mean ± SD of three independent experiments (<span class="html-italic">n</span> = 3). One-way ANOVA followed by Tukey’s test. Statistically significant differences: * <span class="html-italic">p</span> < 0.05; ** <span class="html-italic">p</span> < 0.01; *** <span class="html-italic">p</span> < 0.001. L+ and numbers in the figure represent positive cellular population for the tested marker.</p> "> Figure 12
<p>Schematic model of cell signaling induced by acute and chronic rotenone exposure in DALNs. Rotenone (ROT, black full star) binds to the ubiquinone binding site of mitochondrial complex I (NADH: ubiquinone oxidoreductase), thus preventing electron transfer via flavin mononucleotide (FMN) to coenzyme Q10 (<b>1</b>). Consequently, interruption of the electron transport chain concomitantly generates anion superoxide (O<sub>2</sub><sup>−</sup>) and hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>, <b>2</b>). This last compound is capable of oxidizing the stress sensor protein DJ-1Cys<sup>106</sup>-SH (<b>3</b>) into DJ-1Cys<sup>106</sup>-SO<sub>3</sub> (<b>4</b>) and directly activates LRRK2 (leucine-rich repeat kinase 2) kinase by autophosphorylation (<b>5</b>). Once LRRK2 is phosphorylated at Ser<sup>935</sup>, the active p-(S-<sup>935</sup>)-LRRK2 kinase phosphorylates three major targets: (i) alpha-synuclein (α-Syn) at residue Ser<sup>129</sup> (<b>6</b>), (ii) it inactivates protein peroxiredoxin 3 (PRDX3, <b>7</b>), thus preventing H<sub>2</sub>O<sub>2</sub> catalysis [<a href="#B83-ijms-24-15744" class="html-bibr">83</a>]; (iii) p-(S-<sup>935</sup>)-LRRK2 activates the mitochondrial fission protein DLP-1 (dynamin-like protein 1, <b>8</b>), which, together with the fission protein-1 (Fis-1) receptor, induces an increase in the expression of parkin (PRKN, <b>9</b>), loss of mitochondrial potential (ΔΨm), fragmentation, and aggregation (<b>10</b>). Subsequently, the release of apoptogenic proteins (e.g., cytochrome C) results in the production of cleaved caspase 3 (<b>11</b>), which is responsible for chromatin condensation and DNA fragmentation (<b>12</b>), characteristics typical of apoptosis in DALNs. Alternatively, as shown previously, ROT binds and reduced the enzyme glucosylceramidase beta 1 (GBA1) (<b>13</b>). Moreover, the reduced catalytic activity of GCase results in a limited fusion of autophagosomes (<b>14</b>) and lysosomes (<b>15</b>), leading to their respective accumulation. Acute conditions: ROT 50 μM, 6 h (<span style="color:red">red</span> arrow); chronic conditions: ROT 10 μM, 24 h (<span style="color:blue">blue</span> arrow). Arrow: activates; round pointed arrow: inhibits.</p> ">
Abstract
:1. Introduction
2. Results
2.1. Obtention of a High Yield of Menstrual Stromal Cell-Derived Mature and Functional Dopamine-like Neurons (DALNs) Using the NeuroForsk 2.0 Medium
2.2. Acute Rotenone (ROT) Induces a Higher Loss of Mitochondrial Membrane Potential (ΔΨm), Expression of Parkin (PRKN) Protein, and Colocalization of DRP1 with Mitochondrial TOMM20 Protein than the Chronic Conditions in DALNs
2.3. Acute Rotenone (ROT) Induces a Higher Oxidation of Protein DJ-1, Phosphorylation of LRRK2 Kinase, and Phosphorylation of α-Synuclein Protein Than Chronic Conditions in DALNs
2.4. Acute Rotenone (ROT) Induces a Higher Activation of Caspase 3 (CASP3) Than the Chronic Conditions in DALNs
2.5. Chronic Rotenone (ROT) Induces a Significant Accumulation of Lipidated LC3B, Lysosomes, and Autophagolysosomes in DALNs
2.6. The Inhibitor LRRK2 PF-06447475 (PF-475) Inhibits p-S935-LRKK2 and Cleaved Caspase 3 in DALNs Treated with ROT
2.7. The Inhibitor LRRK2 PF-06447475 (PF-475) Reduces the Accumulation of Lysosomes in DALNs Treated with ROT
3. Discussion
4. Materials and Methods
4.1. Source of Menstrual Stromal Cells (MenSCs)
4.2. Dopaminergic-like Neurons (DALNs) Differentiation
4.3. Immunofluorescence Analysis
4.4. Flow Cytometry Analysis of Dopaminergic Markers
4.5. Intracellular Calcium Imaging
4.6. Detection of oxDJ-1, Phosphorylated LRRK2, Alpha-Synuclein, Cleaved Caspase 3 (CC3), and LC3B Using Fluorescent Microscopy or Flow Cytometry
4.7. Analysis of Mitochondrial Membrane Potential (ΔΨm)
4.8. Characterization of Lysosomal Complexity
4.9. Data Analysis
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Dominici, M.; Blanc, K.L.; Mueller, I.; Slaper-Cortenbach, I.; Marini, F.; Krause, D.; Deans, R.; Keating, A.; Prockop, D.; Horwitz, E.; et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8, 315–317. [Google Scholar] [CrossRef] [PubMed]
- Viswanathan, S.; Shi, Y.; Galipeau, J.; Krampera, M.; Leblanc, K.; Martin, I.; Nolta, J.; Phinney, D.G.; Sensebe, L. Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclature. Cytotherapy 2019, 21, 1019–1024. [Google Scholar] [CrossRef] [PubMed]
- Liu, Y.; Niu, R.; Yang, F.; Yan, Y.; Liang, S.; Sun, Y.; Shen, P.; Lin, J. Biological characteristics of human menstrual blood-derived endometrial stem cells. J. Cell Mol. Med. 2018, 22, 1627–1639. [Google Scholar] [CrossRef] [PubMed]
- Chen, L.; Qu, J.; Cheng, T.; Chen, X.; Xiang, C. Menstrual blood-derived stem cells: Toward therapeutic mechanisms, novel strategies, and future perspectives in the treatment of diseases. Stem Cell Res. Ther. 2019, 10, 406. [Google Scholar] [CrossRef]
- Rahbaran, M.; Zekiy, A.O.; Bahramali, M.; Jahangir, M.; Mardasi, M.; Sakhaei, D.; Thangavelu, L.; Shomali, N.; Zamani, M.; Mohammadi, A.; et al. Therapeutic utility of mesenchymal stromal cell (MSC)-based approaches in chronic neurodegeneration: A glimpse into underlying mechanisms, current status, and prospects. Cell Mol. Biol. Lett. 2022, 27, 56. [Google Scholar] [CrossRef]
- Li, H.; Wei, J.; Zhang, Z.; Li, J.; Ma, Y.; Zhang, P.; Lin, J. Menstrual blood-derived endometrial stem cells alleviate neuroinflammation by modulating M1/M2 polarization in cell and rat Parkinson’s disease models. Stem Cell Res. Ther. 2023, 14, 85. [Google Scholar] [CrossRef]
- Quintero-Espinosa, D.; Soto-Mercado, V.; Quintero-Quinchia, C.; Mendivil-Perez, M.; Velez-Pardo, C.; Jimenez-Del-Rio, M. Latent Tri-lineage Potential of Human Menstrual Blood-Derived Mesenchymal Stromal Cells Revealed by Specific In Vitro Culture Conditions. Mol. Neurobiol. 2021, 58, 5194–5209. [Google Scholar] [CrossRef]
- Marton, R.M.; Ioannidis, J.P.A. A Comprehensive Analysis of Protocols for Deriving Dopaminergic Neurons from Human Pluripotent Stem Cells. Stem Cells Transl. Med. 2019, 8, 366–374. [Google Scholar] [CrossRef]
- Gantner, C.W.; Cota-Coronado, A.; Thompson, L.H.; Parish, C.L. An Optimized Protocol for the Generation of Midbrain Dopamine Neurons under Defined Conditions. STAR Protoc. 2020, 1, 100065. [Google Scholar] [CrossRef]
- Kriks, S.; Shim, J.W.; Piao, J.; Ganat, Y.M.; Wakeman, D.R.; Xie, Z.; Carrillo-Reid, L.; Auyeung, G.; Antonacci, C.; Buch, A.; et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson’s disease. Nature 2011, 480, 547–551. [Google Scholar] [CrossRef]
- Niclis, J.C.; Gantner, C.W.; Alsanie, W.F.; McDougall, S.J.; Bye, C.R.; Elefanty, A.G.; Stanley, E.G.; Haynes, J.M.; Pouton, C.W.; Thompson, L.H.; et al. Efficiently Specified Ventral Midbrain Dopamine Neurons from Human Pluripotent Stem Cells Under Xeno-Free Conditions Restore Motor Deficits in Parkinsonian Rodents. Stem Cells Transl. Med. 2017, 6, 937–948. [Google Scholar] [CrossRef] [PubMed]
- Paldino, E.; Cenciarelli, C.; Giampaolo, A.; Milazzo, L.; Pescatori, M.; Hassan, H.J.; Casalbore, P. Induction of dopaminergic neurons from human Wharton’s jelly mesenchymal stem cell by forskolin. J. Cell Physiol. 2014, 229, 232–244. [Google Scholar] [CrossRef] [PubMed]
- Singh, M.; Vaishnav, P.K.; Dinda, A.K.; Mohanty, S. Evaluation of Priming Efficiency of Forskolin in Tissue-Specific Human Mesenchymal Stem Cells into Dopaminergic Neurons: An In Vitro Comparative Study. Cells 2020, 9, 2058. [Google Scholar] [CrossRef] [PubMed]
- Sae-Yun, A.; Ovatlarnporn, C.; Itharat, A.; Wiwattanapatapee, R. Extraction of rotenone from Derris elliptica and Derris malaccensis by pressurized liquid extraction compared with maceration. J. Chromatogr. A 2006, 1125, 172–176. [Google Scholar] [CrossRef]
- Zubairi, S.I.; Sarmidi, M.R.; Aziz, R.A. A Study of Rotenone from Derris Roots of Varies Location, Plant Parts and Types of Solvent Used. Adv. Environ. Biol. 2014, 8, 445–449. [Google Scholar]
- Fang, N.; Casida, J.E. Cubé resin insecticide: Identification and biological activity of 29 rotenoid constituents. J. Agric. Food Chem. 1999, 47, 2130–2136. [Google Scholar] [CrossRef]
- Goldman, S.M. Environmental toxins and Parkinson’s disease. Annu. Rev. Pharmacol. Toxicol. 2014, 54, 141–164. [Google Scholar] [CrossRef]
- Pouchieu, C.; Piel, C.; Carles, C.; Gruber, A.; Helmer, C.; Tual, S.; Marcotullio, E.; Lebailly, P.; Baldi, I. Pesticide use in agriculture and Parkinson’s disease in the AGRICAN cohort study. Int. J. Epidemiol. 2018, 47, 299–310. [Google Scholar] [CrossRef]
- Dickson, D.W. Parkinson’s disease and parkinsonism: Neuropathology. Cold Spring Harb. Perspect. Med. 2012, 2, a009258. [Google Scholar] [CrossRef]
- Giguère, N.; Burke Nanni, S.; Trudeau, L.E. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson’s Disease. Front. Neurol. 2018, 9, 455. [Google Scholar] [CrossRef]
- Spillantini, M.G.; Schmidt, M.L.; Lee, V.M.; Trojanowski, J.Q.; Jakes, R.; Goedert, M. Alpha-synuclein in Lewy bodies. Nature 1997, 388, 839–840. [Google Scholar] [CrossRef] [PubMed]
- Spillantini, M.G.; Crowther, R.A.; Jakes, R.; Hasegawa, M.; Goedert, M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. USA 1998, 95, 6469–6473. [Google Scholar] [CrossRef] [PubMed]
- Lawana, V.; Cannon, J.R. Chapter Five—Rotenone neurotoxicity: Relevance to Parkinson’s disease. In Advances in Neurotoxicology; Aschner, M., Costa, L.G., Eds.; Academic Press: Cambridge, MA, USA, 2020; Volume 4, pp. 209–254. [Google Scholar]
- Betarbet, R.; Sherer, T.B.; MacKenzie, G.; Garcia-Osuna, M.; Panov, A.V.; Greenamyre, J.T. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat. Neurosci. 2000, 3, 1301–1306. [Google Scholar] [CrossRef] [PubMed]
- Rocha, S.M.; Bantle, C.M.; Aboellail, T.; Chatterjee, D.; Smeyne, R.J.; Tjalkens, R.B. Rotenone induces regionally distinct α-synuclein protein aggregation and activation of glia prior to loss of dopaminergic neurons in C57Bl/6 mice. Neurobiol. Dis. 2022, 167, 105685. [Google Scholar] [CrossRef] [PubMed]
- Ganjam, G.K.; Bolte, K.; Matschke, L.A.; Neitemeier, S.; Dolga, A.M.; Höllerhage, M.; Höglinger, G.U.; Adamczyk, A.; Decher, N.; Oertel, W.H.; et al. Mitochondrial damage by α-synuclein causes cell death in human dopaminergic neurons. Cell Death Dis. 2019, 10, 865. [Google Scholar] [CrossRef]
- Chen, Y.; McMillan-Ward, E.; Kong, J.; Israels, S.J.; Gibson, S.B. Oxidative stress induces autophagic cell death independent of apoptosis in transformed and cancer cells. Cell Death Differ. 2008, 15, 171–182. [Google Scholar] [CrossRef]
- Xiong, N.; Xiong, J.; Jia, M.; Liu, L.; Zhang, X.; Chen, Z.; Huang, J.; Zhang, Z.; Hou, L.; Luo, Z.; et al. The role of autophagy in Parkinson’s disease: Rotenone-based modeling. Behav. Brain Funct. 2013, 9, 13. [Google Scholar] [CrossRef]
- Mader, B.J.; Pivtoraiko, V.N.; Flippo, H.M.; Klocke, B.J.; Roth, K.A.; Mangieri, L.R.; Shacka, J.J. Rotenone inhibits autophagic flux prior to inducing cell death. ACS Chem. Neurosci. 2012, 3, 1063–1072. [Google Scholar] [CrossRef]
- Wu, F.; Xu, H.D.; Guan, J.J.; Hou, Y.S.; Gu, J.H.; Zhen, X.C.; Qin, Z.H. Rotenone impairs autophagic flux and lysosomal functions in Parkinson’s disease. Neuroscience 2015, 284, 900–911. [Google Scholar] [CrossRef]
- Perez-Abshana, L.P.; Mendivil-Perez, M.; Velez-Pardo, C.; Jimenez-Del-Rio, M. Rotenone Blocks the Glucocerebrosidase Enzyme and Induces the Accumulation of Lysosomes and Autophagolysosomes Independently of LRRK2 Kinase in HEK-293 Cells. Int. J. Mol. Sci. 2023, 24, 10589. [Google Scholar] [CrossRef]
- Elkouzi, A.; Vedam-Mai, V.; Eisinger, R.S.; Okun, M.S. Emerging therapies in Parkinson disease—repurposed drugs and new approaches. Nat. Rev. Neurol. 2019, 15, 204–223. [Google Scholar] [CrossRef] [PubMed]
- Dong-Chen, X.; Yong, C.; Yang, X.; Chen-Yu, S.; Li-Hua, P. Signaling pathways in Parkinson’s disease: Molecular mechanisms and therapeutic interventions. Signal Transduct. Target. Ther. 2023, 8, 73. [Google Scholar] [CrossRef] [PubMed]
- Read, A.D.; Bentley, R.E.; Archer, S.L.; Dunham-Snary, K.J. Mitochondrial iron-sulfur clusters: Structure, function, and an emerging role in vascular biology. Redox Biol. 2021, 47, 102164. [Google Scholar] [CrossRef]
- Schiller, J.; Zickermann, V. Binding of Natural Inhibitors to Respiratory Complex I. Pharmaceuticals 2022, 15, 1088. [Google Scholar] [CrossRef]
- Li, N.; Ragheb, K.; Lawler, G.; Sturgis, J.; Rajwa, B.; Melendez, J.A.; Robinson, J.P. Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J. Biol. Chem. 2003, 278, 8516–8525. [Google Scholar] [CrossRef] [PubMed]
- Mailloux, R.J. Teaching the fundamentals of electron transfer reactions in mitochondria and the production and detection of reactive oxygen species. Redox Biol. 2015, 4, 381–398. [Google Scholar] [CrossRef] [PubMed]
- Marinho, H.S.; Real, C.; Cyrne, L.; Soares, H.; Antunes, F. Hydrogen peroxide sensing, signaling and regulation of transcription factors. Redox Biol. 2014, 2, 535–562. [Google Scholar] [CrossRef]
- Antunes, F.; Brito, P.M. Quantitative biology of hydrogen peroxide signaling. Redox Biol. 2017, 13, 1–7. [Google Scholar] [CrossRef]
- Mendivil-Perez, M.; Velez-Pardo, C.; Jimenez-Del-Rio, M. Neuroprotective Effect of the LRRK2 Kinase Inhibitor PF-06447475 in Human Nerve-like Differentiated Cells Exposed to Oxidative Stress Stimuli: Implications for Parkinson’s Disease. Neurochem. Res. 2016, 41, 2675–2692. [Google Scholar] [CrossRef]
- Frank, S.; Gaume, B.; Bergmann-Leitner, E.S.; Leitner, W.W.; Robert, E.G.; Catez, F.; Smith, C.L.; Youle, R.J. The role of dynamin-related protein 1, a mediator of mitochondrial fission, in apoptosis. Dev. Cell 2001, 1, 515–525. [Google Scholar] [CrossRef]
- Tanaka, A.; Youle, R.J. A chemical inhibitor of DRP1 uncouples mitochondrial fission and apoptosis. Mol. Cell 2008, 29, 409–410. [Google Scholar] [CrossRef] [PubMed]
- Anderson, J.P.; Walker, D.E.; Goldstein, J.M.; De Laat, R.; Banducci, K.; Caccavello, R.J.; Barbour, R.; Huang, J.; Kling, K.; Lee, M.; et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 2006, 281, 29739–29752. [Google Scholar] [CrossRef] [PubMed]
- Nakano, M.; Imamura, H.; Sasaoka, N.; Yamamoto, M.; Uemura, N.; Shudo, T.; Fuchigami, T.; Takahashi, R.; Kakizuka, A. ATP Maintenance via Two Types of ATP Regulators Mitigates Pathological Phenotypes in Mouse Models of Parkinson’s Disease. EBioMedicine 2017, 22, 225–241. [Google Scholar] [CrossRef] [PubMed]
- Radad, K.; Al-Shraim, M.; Al-Emam, A.; Wang, F.; Kranner, B.; Rausch, W.D.; Moldzio, R. Rotenone: From modelling to implication in Parkinson’s disease. Folia Neuropathol. 2019, 57, 317–326. [Google Scholar] [CrossRef] [PubMed]
- Ke, M.; Chong, C.M.; Zhu, Q.; Zhang, K.; Cai, C.Z.; Lu, J.H.; Qin, D.; Su, H. Comprehensive Perspectives on Experimental Models for Parkinson’s Disease. Aging Dis. 2021, 12, 223–246. [Google Scholar] [CrossRef]
- Abrishamdar, M.; Jalali, M.S.; Farbood, Y. Targeting Mitochondria as a Therapeutic Approach for Parkinson’s Disease. Cell Mol. Neurobiol. 2023, 43, 1499–1518. [Google Scholar] [CrossRef]
- Tryphena, K.P.; Nikhil, U.S.; Pinjala, P.; Srivastava, S.; Singh, S.B.; Khatri, D.K. Mitochondrial Complex I as a Pathologic and Therapeutic Target for Parkinson’s Disease. ACS Chem. Neurosci. 2023, 14, 1356–1368. [Google Scholar] [CrossRef]
- Testa, C.M.; Sherer, T.B.; Greenamyre, J.T. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Brain Res. Mol. 2005, 134, 109–118. [Google Scholar] [CrossRef]
- Chang, K.-H.; Chen, C.-M. The Role of Oxidative Stress in Parkinson’s Disease. Antioxidants 2020, 9, 597. [Google Scholar] [CrossRef]
- Ge, P.; Dawson, V.L.; Dawson, T.M. PINK1 and Parkin mitochondrial quality control: A source of regional vulnerability in Parkinson’s disease. Mol. Neurodegener. 2020, 15, 20. [Google Scholar] [CrossRef]
- Su, Y.C.; Qi, X. Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation. Hum. Mol. Genet. 2013, 22, 4545–4561. [Google Scholar] [CrossRef]
- Kinumi, T.; Kimata, J.; Taira, T.; Ariga, H.; Niki, E. Cysteine-106 of DJ-1 is the most sensitive cysteine residue to hydrogen peroxide-mediated oxidation in vivo in human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun. 2004, 317, 722–728. [Google Scholar] [CrossRef] [PubMed]
- Li, X.; Patel, J.C.; Wang, J.; Avshalumov, M.V.; Nicholson, C.; Buxbaum, J.D.; Elder, G.A.; Rice, M.E.; Yue, Z. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson’s disease mutation G2019S. J. Neurosci. 2010, 30, 1788–1797. [Google Scholar] [CrossRef] [PubMed]
- Qing, H.; Wong, W.; McGeer, E.G.; McGeer, P.L. Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications. Biochem. Biophys. Res. Commun. 2009, 387, 149–152. [Google Scholar] [CrossRef] [PubMed]
- Crowley, L.C.; Waterhouse, N.J. Detecting Cleaved Caspase-3 in Apoptotic Cells by Flow Cytometry. Cold Spring Harb. Protoc. 2016, 2016, 958–962. [Google Scholar] [CrossRef]
- Zhang, J. Teaching the basics of autophagy and mitophagy to redox biologists–mechanisms and experimental approaches. Redox Biol. 2015, 4, 242–259. [Google Scholar] [CrossRef]
- Zappavigna, S.; Lombardi, A.; Misso, G.; Grimaldi, A.; Caraglia, M. Measurement of Autophagy by Flow Cytometry. Methods Mol. Biol. 2017, 1553, 209–216. [Google Scholar] [CrossRef]
- Bonilla-Porras, A.R.; Velez-Pardo, C.; Jimenez-Del-Rio, M. Fast transdifferentiation of human Wharton’s jelly mesenchymal stem cells into neurospheres and nerve-like cells. J. Neurosci. Methods 2017, 282, 52–60. [Google Scholar] [CrossRef]
- Hu, X.; Mao, C.; Fan, L.; Luo, H.; Hu, Z.; Zhang, S.; Yang, Z.; Zheng, H.; Sun, H.; Fan, Y.; et al. Modeling Parkinson’s Disease Using Induced Pluripotent Stem Cells. Stem. Cells Int. 2020, 2020, 1061470. [Google Scholar]
- Seamon, K.B.; Daly, J.W. Forskolin: A unique diterpene activator of cyclic AMP-generating systems. J. Cycl. Nucleotide Res. 1981, 7, 201–224. [Google Scholar]
- Thompson, R.; Casali, C.; Chan, C. Forskolin and IBMX Induce Neural Transdifferentiation of MSCs through Downregulation of the NRSF. Sci. Rep. 2019, 9, 2969. [Google Scholar] [CrossRef] [PubMed]
- Yeap, Y.J.; Teddy, T.J.W.; Lee, M.J.; Goh, M.; Lim, K.L. From 2D to 3D: Development of Monolayer Dopaminergic Neuronal and Midbrain Organoid Cultures for Parkinson’s Disease Modeling and Regenerative Therapy. Int. J. Mol. Sci. 2023, 24, 2523. [Google Scholar] [CrossRef]
- Skaper, S.D. Neurotrophic Factors: An Overview. In Neurotrophic Factors; Humana: New York, NY, USA, 2018; Volume 1727, pp. 1–17. [Google Scholar] [CrossRef]
- Farooq, M.; Khan, A.W.; Kim, M.S.; Choi, S. The Role of Fibroblast Growth Factor (FGF) Signaling in Tissue Repair and Regeneration. Cells 2021, 10, 3242. [Google Scholar] [CrossRef] [PubMed]
- Sinha, S.; Chen, J.K. Purmorphamine activates the Hedgehog pathway by targeting Smoothened. Nat. Chem. Biol. 2006, 2, 29–30. [Google Scholar] [CrossRef] [PubMed]
- Belgacem, Y.H.; Hamilton, A.M.; Shim, S.; Spencer, K.A.; Borodinsky, L.N. The Many Hats of Sonic Hedgehog Signaling in Nervous System Development and Disease. J. Dev. Biol. 2016, 4, 35. [Google Scholar] [CrossRef]
- Mendivil-Perez, M.; Soto-Mercado, V.; Guerra-Librero, A.; Fernandez-Gil, B.I.; Florido, J.; Shen, Y.Q.; Tejada, M.A.; Capilla-Gonzalez, V.; Rusanova, I.; Garcia-Verdugo, J.M.; et al. Melatonin enhances neural stem cell differentiation and engraftment by increasing mitochondrial function. J. Pineal Res. 2017, 63, e12415. [Google Scholar] [CrossRef]
- Catoni, C.; Calì, T.; Brini, M. Calcium, Dopamine and Neuronal Calcium Sensor 1: Their Contribution to Parkinson’s Disease. Front. Mol. Neurosci. 2019, 12, 55. [Google Scholar] [CrossRef]
- Velez-Pardo, C.; Jimenez-Del-Rio, M. Chapter 10—Oxidative Stress Signaling and Regulated Cell Death in Parkinson’s Disease. In Genetics, Neurology, Behavior, and Diet in Parkinson’s Disease; Martin, C.R., Preedy, V.R., Eds.; Academic Press: Cambridge, UK, 2020; pp. 157–173. [Google Scholar]
- Quintero-Espinosa, D.A.; Sanchez-Hernandez, S.; Velez-Pardo, C.; Martin, F.; Jimenez-Del-Rio, M. LRRK2 Knockout Confers Resistance in HEK-293 Cells to Rotenone-Induced Oxidative Stress, Mitochondrial Damage, and Apoptosis. Int. J. Mol. Sci. 2023, 24, 10474. [Google Scholar] [CrossRef]
- Moreau, K.; Luo, S.; Rubinsztein, D.C. Cytoprotective roles for autophagy. Curr. Opin. Cell. Biol. 2010, 22, 206–211. [Google Scholar]
- Stavoe, A.K.H.; Holzbaur, E.L.F. Autophagy in Neurons. Annu. Rev. Cell Dev. Biol. 2019, 35, 477–500. [Google Scholar] [CrossRef]
- Denton, D.; Kumar, S. Autophagy-dependent cell death. Cell Death Differ. 2019, 26, 605–616. [Google Scholar] [CrossRef] [PubMed]
- Liu, Y.; Shoji-Kawata, S.; Sumpter, R.M., Jr.; Wei, Y.; Ginet, V.; Zhang, L.; Posner, B.; Tran, K.A.; Green, D.R.; Xavier, R.J.; et al. Autosis is a Na+,K+-ATPase-regulated form of cell death triggered by autophagy-inducing peptides, starvation, and hypoxia-ischemia. Proc. Natl. Acad. Sci. USA 2013, 110, 20364–20371. [Google Scholar] [CrossRef] [PubMed]
- Yarmohammadi, F.; Wallace Hayes, A.; Najafi, N.; Karimi, G. The protective effect of natural compounds against rotenone-induced neurotoxicity. J. Biochem. Mol. Toxicol. 2020, 34, e22605. [Google Scholar] [CrossRef]
- Moghaddam, S.A.; Yousefi, B.; Sanooghi, D.; Faghihi, F.; Hayati Roodbari, N.; Bana, N.; Joghataei, M.T.; Pooyan, P.; Arjmand, B. Differentiation potential of human CD133 positive hematopoietic stem cells into motor neuron- like cells, in vitro. J. Chem. Neuroanat. 2017, 86, 35–40. [Google Scholar] [CrossRef] [PubMed]
- Fathi, A.; Mirzaei, M.; Dolatyar, B.; Sharifitabar, M.; Bayat, M.; Shahbazi, E.; Lee, J.; Javan, M.; Zhang, S.C.; Gupta, V.; et al. Discovery of Novel Cell Surface Markers for Purification of Embryonic Dopamine Progenitors for Transplantation in Parkinson’s Disease Animal Models. Mol. Cell Proteom. 2018, 17, 1670–1684. [Google Scholar] [CrossRef]
- Pap, P.; Koszeghy, A.; Szucs, G.; Rusznák, Z. Cytoplasmic Ca(2+) concentration changes evoked by cholinergic stimulation in primary astrocyte cultures prepared from the rat cochlear nucleus. Hear. Res. 2009, 255, 73–83. [Google Scholar] [CrossRef] [PubMed]
- Mendivil-Perez, M.; Velez-Pardo, C.; Jimenez-Del-Rio, M. Direct transdifferentiation of human Wharton’s jelly mesenchymal stromal cells into cholinergic-like neurons. J. Neurosci. Methods 2019, 312, 126–138. [Google Scholar] [CrossRef] [PubMed]
- Monteiro, L.B.; Davanzo, G.G.; De Aguiar, C.F.; Moraes-Vieira, P.M.M. Using flow cytometry for mitochondrial assays. MethodsX 2020, 7, 100938. [Google Scholar] [CrossRef]
- Lazic, S.E.; Clarke-Williams, C.J.; Munafò, M.R. What exactly is ‘N’ in cell culture and animal experiments? PLoS Biol. 2018, 16, e2005282. [Google Scholar] [CrossRef]
- Angeles, D.C.; Gan, B.H.; Onstead, L.; Zhao, Y.; Lim, K.L.; Dachsel, J.; Melrose, H.; Farrer, M.; Wszolek, Z.K.; Dickson, D.W.; et al. Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating oxidative stress-induced neuronal death. Hum. Mutat. 2011, 32, 1390–1397. [Google Scholar] [CrossRef]
Condition/Variable | Acute (50 μM, 6 h) | Chronic (10 μM, 24 h) | Acute vs. Chronic |
---|---|---|---|
ΔΨm | −49% | −13% | −39% |
PRKN | +514% | +363% | +16% |
DRP1 | +85% | +50% | +41% |
DJ-1Cys106-SO3 | +1300% | +583% | +71% |
pSer935-LRRK2 | +750% | +266% | +210% |
pSer129-α-Syn | +550% | +183% | +53% |
CC3 | +1500% | +500% | +78% |
LC3B | +460% | +400% | −30% |
Lysosome | +104% | +146% | −18% |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Quintero-Espinosa, D.A.; Velez-Pardo, C.; Jimenez-Del-Rio, M. High Yield of Functional Dopamine-like Neurons Obtained in NeuroForsk 2.0 Medium to Study Acute and Chronic Rotenone Effects on Oxidative Stress, Autophagy, and Apoptosis. Int. J. Mol. Sci. 2023, 24, 15744. https://doi.org/10.3390/ijms242115744
Quintero-Espinosa DA, Velez-Pardo C, Jimenez-Del-Rio M. High Yield of Functional Dopamine-like Neurons Obtained in NeuroForsk 2.0 Medium to Study Acute and Chronic Rotenone Effects on Oxidative Stress, Autophagy, and Apoptosis. International Journal of Molecular Sciences. 2023; 24(21):15744. https://doi.org/10.3390/ijms242115744
Chicago/Turabian StyleQuintero-Espinosa, Diana Alejandra, Carlos Velez-Pardo, and Marlene Jimenez-Del-Rio. 2023. "High Yield of Functional Dopamine-like Neurons Obtained in NeuroForsk 2.0 Medium to Study Acute and Chronic Rotenone Effects on Oxidative Stress, Autophagy, and Apoptosis" International Journal of Molecular Sciences 24, no. 21: 15744. https://doi.org/10.3390/ijms242115744
APA StyleQuintero-Espinosa, D. A., Velez-Pardo, C., & Jimenez-Del-Rio, M. (2023). High Yield of Functional Dopamine-like Neurons Obtained in NeuroForsk 2.0 Medium to Study Acute and Chronic Rotenone Effects on Oxidative Stress, Autophagy, and Apoptosis. International Journal of Molecular Sciences, 24(21), 15744. https://doi.org/10.3390/ijms242115744